JMP Securities Reinstates Market Perform on Iovance Biotherapeutics, Maintains $18 Price Target
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Reni Benjamin reinstated Iovance Biotherapeutics (NASDAQ:IOVA) with a Market Perform rating and maintained an $18 price target.
May 30, 2023 | 12:31 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
JMP Securities reinstated Iovance Biotherapeutics with a Market Perform rating and maintained an $18 price target.
The reinstatement of Iovance Biotherapeutics with a Market Perform rating by JMP Securities indicates a neutral outlook for the stock. The maintained $18 price target suggests that the analyst believes the stock is fairly valued. This news is directly related to IOVA and is important for investors, but it is not expected to have a significant short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100